5-132579996-GT-G
Variant summary
Our verdict is Pathogenic. Variant got 16 ACMG points: 16P and 0B. PVS1PP5_Very_Strong
The NM_005732.4(RAD50):βc.687delβ(p.Ser229ArgfsTer6) variant causes a frameshift change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.000177 in 1,613,386 control chromosomes in the GnomAD database, with no homozygous occurrence. Variant has been reported in ClinVar as Likely pathogenic (β β ). Synonymous variant affecting the same amino acid position (i.e. S229S) has been classified as Likely benign. Variant results in nonsense mediated mRNA decay.
Frequency
Consequence
NM_005732.4 frameshift
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Pathogenic. Variant got 16 ACMG points.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | UniProt |
---|---|---|---|---|---|---|---|
RAD50 | NM_005732.4 | c.687del | p.Ser229ArgfsTer6 | frameshift_variant | 5/25 | ENST00000378823.8 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|
RAD50 | ENST00000378823.8 | c.687del | p.Ser229ArgfsTer6 | frameshift_variant | 5/25 | 1 | NM_005732.4 | P1 |
Frequencies
GnomAD3 genomes AF: 0.000401 AC: 61AN: 152188Hom.: 0 Cov.: 32
GnomAD3 exomes AF: 0.000462 AC: 116AN: 251160Hom.: 0 AF XY: 0.000442 AC XY: 60AN XY: 135762
GnomAD4 exome AF: 0.000153 AC: 224AN: 1461080Hom.: 0 Cov.: 31 AF XY: 0.000161 AC XY: 117AN XY: 726894
GnomAD4 genome AF: 0.000401 AC: 61AN: 152306Hom.: 0 Cov.: 32 AF XY: 0.000658 AC XY: 49AN XY: 74486
ClinVar
Submissions by phenotype
Hereditary cancer-predisposing syndrome Pathogenic:2
Pathogenic, criteria provided, single submitter | clinical testing | Ambry Genetics | Apr 28, 2023 | The c.687delT pathogenic mutation, located in coding exon 5 of the RAD50 gene, results from a deletion of one nucleotide at nucleotide position 687, causing a translational frameshift with a predicted alternate stop codon (p.S229Rfs*6). This alteration was first reported in 2/151 Finnish familial breast/ovarian cancer individuals as well as in 6/1000 cancer free controls (Heikkinen K, J. Med. Genet. 2003 Dec; 40(12):e131). In a case control study of 317 consecutive newly diagnosed Finnish breast cancer patients and 1000 geographically matched healthy controls, eight breast cancer patients and six controls were carriers (95% CI 1.5–12.5, P = 0.008). Haplotype analysis suggests this is a Finnish founder mutation (Heikkinen K, Carcinogenesis 2006 Aug; 27(8):1). In addition to the clinical data presented in the literature, this alteration is expected to result in loss of function by premature protein truncation or nonsense-mediated mRNA decay. As such, this alteration is interpreted as a disease-causing mutation. - |
Pathogenic, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Sep 14, 2023 | Algorithms developed to predict the effect of variants on protein structure and function are not available or were not evaluated for this variant. For these reasons, this variant has been classified as Pathogenic. Experimental studies have shown that this premature translational stop signal affects RAD50 function (PMID: 14684699, 16385572, 16474176). ClinVar contains an entry for this variant (Variation ID: 185010). This premature translational stop signal has been observed in individual(s) with hereditary breast and ovarian cancer in that population (PMID: 14684699, 16385572, 16474176, 25452441). It is commonly reported in individuals of Finnish ancestry (PMID: 14684699, 16385572, 16474176, 25452441). This variant is present in population databases (rs760146707, gnomAD 0.4%), and has an allele count higher than expected for a pathogenic variant. This sequence change creates a premature translational stop signal (p.Ser229Argfs*6) in the RAD50 gene. It is expected to result in an absent or disrupted protein product. Loss-of-function variants in RAD50 are known to be pathogenic (PMID: 19409520). - |
Nijmegen breakage syndrome-like disorder Pathogenic:2
Pathogenic, criteria provided, single submitter | clinical testing | Baylor Genetics | Jun 15, 2022 | - - |
Likely pathogenic, criteria provided, single submitter | clinical testing | Counsyl | Jun 13, 2016 | - - |
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at